ASPREE Results Support FDA Aspirin Label Guidance On Cardiovascular Disease
Executive Summary
Data from ASPREE trial with more than 19,000 subjects show five-year-use of low-dose aspirin did not prolong disability-free survival and is associated with a significantly higher rate of hemorrhage and somewhat higher rate of all-cause mortality. Findings in three reports in NEJM track with US FDA's guidance that OTC aspirin marketers include a statement referring to doctors when aspirin package labels include a heart or other image suggesting a CV indication.
You may also be interested in...
FDA Adds 'Doctor' To CV Statement For OTC Aspirin Labeled With Hearts
In response to the US agency's guidance announced Nov. 6, the pharmaceutical firm whose name is synonymous with the ingredient aspirin, Bayer, says it is considering how it will change labeling now used for most Bayer Aspirin products that includes a statement similar to the recommended language.
FDA Denies Bayer Petition For Aspirin As Primary Prevention Of Heart Attack, Stroke
Aspirin’s potential to prevent a first stroke or heart attack if used regularly does not outweigh the risks, including increased bleeding in the stomach and brain, FDA tells Bayer Healthcare in a letter denying the firm’s request to market the drug for primary prevention.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.